PHARM.AS Pharming Group N.V. EURONEXT -16.58% to €1.44 after hours 02 Feb 2026: FDA CRL

PHARM.AS stock fell sharply after hours on 02 Feb 2026 after Pharming Group N.V. (PHARM.AS) confirmed an FDA Complete Response Letter tied to its pediatric sNDA for Joenja. The share price traded at €1.44 after hours, a -16.58% move on heavy turnover of 58,182,900.00 shares. Investors focused on dose-exposure data and analytical-method questions from the FDA. This sell-off put PHARM.AS among the most active names on EURONEXT in after-hours trading as market participants reprice regulatory risk and wait for a Type A meeting request

PHARM.AS stock: market snapshot and after-hours trade

PHARM.AS (Pharming Group N.V.) closed the regular session lower and traded €1.44 in after-hours action on 02 Feb 2026. The one-day decline was -16.58%, with a day range €1.37–€1.53 and year range €0.66–€1.82. Volume surged to 58,182,900.00 versus an average of 17,783,362.00, marking PHARM.AS among the most active Euronext stocks in the session. Technicals showed an RSI of 71.76, signalling short-term strength before the news-driven reversal

Regulatory trigger: FDA Complete Response Letter and impact

Pharming said the U.S. FDA issued a Complete Response Letter for the sNDA seeking Joenja approval in children aged 4–11. The FDA flagged potential underexposure in lower-weight pediatric patients and an analytical-method issue for batch testing. Management plans to request a Type A meeting and supply additional pediatric PK and assay data. The announcement is the clear proximate cause of today’s after-hours move and explains the volume spike and selling pressure source.

Valuation and financials: what the numbers show

Pharming’s market cap stands near €1,192,730,265.00 with trailing EPS -0.01 and a negative PE metric. Key ratios: price-to-sales 3.90, price-to-book 5.13, and free-cash-flow yield 3.73%. The balance sheet shows a current ratio 3.16, and net-debt-to-EBITDA is slightly negative, signalling net cash. Revenue growth was 16.95% in FY 2024 while EPS dipped. These metrics frame why investors value Pharming as a clinical-stage commercial biotech rather than a stable dividend play

Meyka AI grade and model forecast for PHARM.AS

Meyka AI rates PHARM.AS with a score out of 100: 64.12 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly target of €1.99 and a three-year target of €3.16. Versus the current price €1.439, the one-year projection implies an upside of +38.07%. Forecasts are model-based projections and not guarantees.

Clinical pipeline and catalysts to watch

Joenja (leniolisib) remains approved for patients aged 12 and older; the CRL affects the 4–11 filing only. Key near-term catalysts: the Type A meeting outcome, additional pediatric PK submissions, and the company’s earnings call on 12 Mar 2026. Positive resolution of the PK and assay items would likely reprice risk and could restore access to the U.S. pediatric market. Negative or prolonged back-and-forth with the FDA would sustain volatility

Technicals, liquidity and trading strategy for most-active traders

For active traders, PHARM.AS shows high intraday volatility and elevated volume. Support sits near the 200-day average €1.17 and the recent low €0.66. Resistance aligns with the 50-day average €1.49 and the year high €1.82. On-chain signals: ATR €0.05, MFI 75.61, and a strong OBV. A tactical approach is to wait for clarity from the FDA meeting or to use tight stops given the stock’s leverage to regulatory news

Final Thoughts

PHARM.AS stock moved to the top of the after-hours most-active list on 02 Feb 2026 after Pharming received an FDA Complete Response Letter for the Joenja pediatric sNDA. The immediate market reaction was a -16.58% drop to €1.44 on volume of 58,182,900.00 shares. The CRL centres on pediatric exposure in lower-weight groups and an analytical-method question; management plans a Type A meeting and additional data submission. From a valuation view, Pharming trades with a price-to-sales of 3.90 and free-cash-flow yield near 3.73%, while cash and current ratios support runway. Meyka AI’s model projects a one-year target of €1.99 (implied +38.07% vs €1.439 current), and a three-year target of €3.16. Given regulatory uncertainty, our view echoes the Meyka grade: HOLD for medium-term investors while active traders may prefer event-driven entry points. For updates, monitor the Type A meeting schedule and the 12 Mar 2026 earnings announcement

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.